Clinical Trial Update: Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

The document indicates that the Phase 1/2 clinical trial of YH25448 in EGFR mutation-positive advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• YH25448

Snippet

Sponsor: Yuhan Corporation | Conditions: EGFR Gene Mutation | Phase 1, Phase 2 | Status: COMPLETED